SG11201810916WA - IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL - Google Patents
IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyLInfo
- Publication number
- SG11201810916WA SG11201810916WA SG11201810916WA SG11201810916WA SG11201810916WA SG 11201810916W A SG11201810916W A SG 11201810916WA SG 11201810916W A SG11201810916W A SG 11201810916WA SG 11201810916W A SG11201810916W A SG 11201810916WA SG 11201810916W A SG11201810916W A SG 11201810916WA
- Authority
- SG
- Singapore
- Prior art keywords
- maryland
- international
- dcfpyl
- pct
- improved synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348391P | 2016-06-10 | 2016-06-10 | |
| PCT/US2017/036681 WO2017214470A1 (en) | 2016-06-10 | 2017-06-09 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810916WA true SG11201810916WA (en) | 2019-01-30 |
Family
ID=60579003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810916WA SG11201810916WA (en) | 2016-06-10 | 2017-06-09 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10947197B2 (ko) |
| EP (1) | EP3481804A4 (ko) |
| JP (3) | JP7054390B2 (ko) |
| KR (2) | KR102558962B1 (ko) |
| CN (1) | CN109563038A (ko) |
| CA (1) | CA3026889A1 (ko) |
| SG (1) | SG11201810916WA (ko) |
| WO (1) | WO2017214470A1 (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113563262A (zh) * | 2008-08-01 | 2021-10-29 | 约翰.霍普金斯大学 | Psma-结合剂及其用途 |
| CN109563038A (zh) | 2016-06-10 | 2019-04-02 | 约翰霍普金斯大学 | 放射性标记的前列腺特异性膜抗原(PSMA)抑制剂[18F]DCFPyL的改进的合成 |
| DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
| DK3765097T3 (da) * | 2018-03-16 | 2022-05-23 | Univ Koeln | 2-alkoxy-6-[18f]fluornicotinoylsubstituerede lys-c(o)-glu-derivater som effektive prober til billeddannelse af psma-udtrykkende væv |
| US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
| US20220387635A1 (en) * | 2019-11-04 | 2022-12-08 | Board Of Regents, The University Of Texas System | Pet imaging of cancerous cells using 18f-fluoroacetate |
| CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
| CN114014843B (zh) * | 2021-11-17 | 2022-09-20 | 北京大学第一医院 | 一种psma靶向核素/荧光双模态配体和分子探针与应用 |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422004D0 (en) | 2004-10-05 | 2004-11-03 | Amersham Plc | Method of deprotection |
| CN113563262A (zh) * | 2008-08-01 | 2021-10-29 | 约翰.霍普金斯大学 | Psma-结合剂及其用途 |
| WO2013173583A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Psma inhibitors |
| US10112974B2 (en) | 2014-08-24 | 2018-10-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer |
| CN109563038A (zh) | 2016-06-10 | 2019-04-02 | 约翰霍普金斯大学 | 放射性标记的前列腺特异性膜抗原(PSMA)抑制剂[18F]DCFPyL的改进的合成 |
-
2017
- 2017-06-09 CN CN201780048128.7A patent/CN109563038A/zh active Pending
- 2017-06-09 JP JP2018563832A patent/JP7054390B2/ja active Active
- 2017-06-09 CA CA3026889A patent/CA3026889A1/en active Pending
- 2017-06-09 SG SG11201810916WA patent/SG11201810916WA/en unknown
- 2017-06-09 EP EP17811054.0A patent/EP3481804A4/en active Pending
- 2017-06-09 US US16/308,128 patent/US10947197B2/en active Active
- 2017-06-09 KR KR1020197000806A patent/KR102558962B1/ko active IP Right Grant
- 2017-06-09 WO PCT/US2017/036681 patent/WO2017214470A1/en unknown
- 2017-06-09 KR KR1020237024616A patent/KR20230111272A/ko not_active Application Discontinuation
-
2021
- 2021-03-09 US US17/195,895 patent/US11851407B2/en active Active
-
2022
- 2022-04-01 JP JP2022062132A patent/JP7427703B2/ja active Active
-
2024
- 2024-01-24 JP JP2024008772A patent/JP2024056729A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230111272A (ko) | 2023-07-25 |
| JP2022101579A (ja) | 2022-07-06 |
| JP2019521104A (ja) | 2019-07-25 |
| JP7427703B2 (ja) | 2024-02-05 |
| EP3481804A1 (en) | 2019-05-15 |
| US10947197B2 (en) | 2021-03-16 |
| US20220055991A1 (en) | 2022-02-24 |
| US20190177275A1 (en) | 2019-06-13 |
| CA3026889A1 (en) | 2017-12-14 |
| JP7054390B2 (ja) | 2022-04-13 |
| CN109563038A (zh) | 2019-04-02 |
| WO2017214470A1 (en) | 2017-12-14 |
| EP3481804A4 (en) | 2019-11-13 |
| JP2024056729A (ja) | 2024-04-23 |
| US11851407B2 (en) | 2023-12-26 |
| KR20190011804A (ko) | 2019-02-07 |
| KR102558962B1 (ko) | 2023-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810916WA (en) | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201900274VA (en) | Event trigger for independent links | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201902942XA (en) | Brake pad and braking unit for capturing particles | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804482UA (en) | Search and retrieval data processing system for computing near real-time data aggregations | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201809846UA (en) | Color table compression | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201901351UA (en) | A patient interface, system and method | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201804435SA (en) | Network security agent | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201809474TA (en) | Compositions and methods for bioengineered tissues |